Nikolaos Petrogiannis

Nikolaos Petrogiannis

Auto-generated profile, based on publicly available information

Nikolaos Petrogiannis


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 January 2022 in Medicina
Verified
Journal Article
Open access
PDF file
KCKaterina Chatzimeletiou
Katerina Chatzimeletiou
AFAlexandra Fleva
Alexandra Fleva
ASAntonia Sioga
Antonia Sioga
Ioannis GeorgiouIoannis Georgiou
Ioannis Georgiou
TNTheodoros Thomas Nikolopoulos
Theodoros Thomas Nikolopoulos
GGGrigoris Grimbizis
Grigoris Grimbizis
Background and Objectives: Ankylosing spondylitis (AS) is a condition that affects 0.1% to 0.5% of the adult population. The aim of this case report was to investigate the possible effects of the drugs taken for treatment of AS as well as mRNA vaccination for COVID-19 on semen quality by performing a highly detailed analysis. Materials and Methods: Sperm characteristics were examined by light microscopy, DNA fragmentation (DFI) was analysed by flow cytometry and morphology was evaluated by transmission electron microscopy (TEM). Results: Semen analysis under therapy with (1) celecoxib and sulphasalazine showed: concentration 47 million/mL, 53% progressive motility, 7% normal morphology and 9.6% DFI, (2) Golimumab and before mRNA Vaccination showed: concentration 108 million/mL, 82% progressive motility, 1% normal morphology and 7.6% DFI, and (3) Golimumab and after 3 doses of mRNA Vaccination showed: concentration 142 million/mL, 85% progressive motility, 1% normal morphology and 6.8% DFI. TEM revealed head, neck and tail abnormalities, as well as the presence of cells with incomplete spermiogenesis white cells and phagocytes in the sample under therapy with celecoxib and sulphasalazine. Golimumab treatment lead to an increased incidence of elongated heads but in general reduced inflammation as no white cells were evident in TEM. Conclusion: The anti-inflamatory drugs celecoxib and sulphasalazine had no adverse effect on sperm quality as all parameters were within normal limits and the patient achieved under that treatment 2 pregnancies following natural conception that lead to the birth of a healthy boy and girl respectively. Anti-TNFa treatment with Golimumab exerted a negative effect on morphology but not on concentration, motility and DFI. After 3 doses of mRNA Vaccination, sperm concentration increased while motility, morphology and DFI remained similar to the values before vaccination suggesting no negative effect of the mRNA vaccine for COVID-19 on sperm quality.

20 February 2025 in Medicina
Verified
Journal Article
Open access
PDF file
NPNikos Petrogiannis
Nikos Petrogiannis
MFMaria Filippa
Maria Filippa
KCKalliopi Chatzovoulou
Kalliopi Chatzovoulou
SPSavvas Petrogiannis
Savvas Petrogiannis
IFIoannis Filippas
Ioannis Filippas
KCKaterina Chatzimeletiou
Katerina Chatzimeletiou
Advancements in assisted reproductive technologies (ARTs) have led to the development of various add-on techniques aimed at improving oocyte quality and enhancing embryo implantation potential. These techniques target critical stages of both oocyte and embryo physiology, including oocyte growth and maturation, fertilization, chromosomal status, and embryo development. Key approaches involve the optimization of in vitro fertilization (IVF) protocols, recruiting capable follicles giving rise to dynamic oocytes to evolve, culture media supplementation, preimplantation genetic testing (PGT), and mitochondrial replacement therapy (MRT), all of which are designed to enhance oocyte competence through its function and metabolism. The use of PGT has been promising in selecting embryos suitable for transfer, thus optimizing implantation success. Emerging technologies, such as platelet-rich plasma treatment (PRP), time-lapse imaging (TLI), and hyaluronan-rich (HA) culture media, claim to improve ovarian rejuvenation and uterine receptivity, embryo selection, as well as embryo implantation potential, respectively. Evidence for certain add-on approaches remains limited, but ongoing research suggests that the use of such treatments may lead to increased clinical pregnancies and live birth rates, especially in poor-prognosis patients. The present review describes the current state of the add-on innovations, their mechanisms of action, as well as their possibilities to increase ART success rates.

20 October 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
PDPanagiota Dourou
Panagiota Dourou
KGKleanthi Gourounti
Kleanthi Gourounti
Vaidas JotautisVaidas Jotautis
Vaidas Jotautis
KLKaterina Lykeridou
Katerina Lykeridou
STSofia Theodorou
Sofia Theodorou
Antigoni SarantakiAntigoni Sarantaki
Antigoni Sarantaki
Background: Multiple Sclerosis (MS) is a chronic neurological disease that commonly affects women during their reproductive years, influencing fertility and family planning decisions. This study explores the psychological, social, and medical factors associated with reproductive choices in women with MS. Objectives: To identify factors influencing reproductive choices in women with MS and assess the role of psychological, social, and disease-related variables in fertility decision. Methods: A cross-sectional study was conducted among 103 women diagnosed with MS, recruited from specialized clinics and support groups. Participants completed validated questionnaires assessing social support, psychological well-being, relationship dynamics, reproductive motivation, and quality of life. Binary logistic regression was performed to identify independent predictors of childbearing. Results: Women with relapsing-remitting MS (73.9%) were significantly more likely to have children than those with progressive forms (p = 0.001), while those using fingolimod (100%) remained childless (p = 0.008). Higher mental health scores (p = 0.035) and fatalistic motivation (p = 0.005) were associated with childbearing, while increased health-related concerns (p = 0.006) were more prevalent among mothers. Marital status (p = 0.001) was a significant factor, with all unmarried women being childless. However, logistic regression analysis did not identify any single independent predictor of childbearing (p > 0.05), suggesting that reproductive decisions are influenced by multiple interrelated factors rather than a single dominant variable. Conclusions: This study highlights the complex interplay of disease progression, psychological resilience, and treatment choices in reproductive decisions among women with MS. Findings emphasize the need for individualized reproductive counseling, considering both medical and psychosocial factors. Future research should incorporate longitudinal studies to better understand the evolving reproductive trajectories of women with MS.

20 March 2026 in Reproductive Medicine
Verified
Journal Article
Open access
PDF file
IBIoanna Bogiatzi
Ioanna Bogiatzi
GKGiannoula Kyrkou
Giannoula Kyrkou
KGKleanthi Gourounti
Kleanthi Gourounti
ABAnastasia Bothou
Anastasia Bothou
ETEleni Tsoukala
Eleni Tsoukala
Antigoni SarantakiAntigoni Sarantaki
Antigoni Sarantaki
Background: Oocyte cryopreservation has emerged as a viable fertility preservation method, gaining popularity among women delaying motherhood for non-medical reasons. This study examines the awareness, perceptions, and social factors influencing young women’s decisions regarding elective oocyte cryopreservation (EOC), intending to identify key demographic and psychosocial determinants. Methods: A cross-sectional study was conducted using an online survey distributed via digital platforms between November 2024 and February 2025. A structured questionnaire comprising 31 multiple-choice questions assessed participants’ sociodemographic characteristics, reproductive health history, lifestyle factors, and perceptions of fertility and EOC. Statistical analyses included Chi-square tests, t-tests, and binary logistic regression to identify factors associated with willingness to undergo EOC. Results: A total of 390 women (mean age 22.57 ± 1.41 years) participated. Awareness of oocyte cryopreservation was remarkably high (93.1%). Significant predictors for the intention to undergo EOC included higher educational attainment (Master’s level) (OR = 4.27, 95% CI: 1.10–16.48) and living in a student dormitory (OR = 15.39, 95% CI: 4.86–48.71). Conversely, living with a partner showed a non-significant downward trend in interest (OR = 0.07, 95% CI: 0.01–1.43). Psychological factors, specifically anxiety about future fertility (OR = 0.23, 95% CI: 0.08–0.62 for moderate vs. high anxiety) and a strong desire for future parenthood (OR = 21.75, 95% CI: 1.45–32.99), also emerged as primary drivers of women’s reproductive decisions. Conclusions: Despite high awareness, the willingness to undergo elective oocyte cryopreservation remains limited. Targeted fertility education and supportive policies are needed to address misconceptions, financial barriers, and psychological concerns influencing reproductive decision-making. Further research should explore longitudinal trends in women’s attitudes toward EOC.

30 September 2024 in Global Reproductive Health
Verified
Journal Article
Open access
NPNikolaos Md Petrogiannis
Nikolaos Md Petrogiannis
KCKaterina Bsc Chatzimeletiou
Katerina Bsc Chatzimeletiou
SPSavvas Petrogiannis
Savvas Petrogiannis
DTDimitrios Traxanas
Dimitrios Traxanas
TAThomas Akrivos
Thomas Akrivos
EAEletherios Anastasakis
Eletherios Anastasakis
The aim of the present study was to analyze the high-quality blastocyst (HB) rate in all embryo frozen cycles and investigate the pregnancy outcomes for day 5/day 6 (D5/D6) blastocysts with respect to the blastocyst quality in programmed single vitrified-warmed blastocyst transfer (SVBT). We performed a retrospective study comparing D5/D6 HBs in in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) for all blastocyst frozen cycles. Patients were below 37 years at the oocyte collection in their first fresh cycle without fresh transfer. A total of 195 IVF/ICSI cycles and 670 blastocysts were analyzed. The IVF HB rate was higher than that of ICSI (52.7% vs. 42.6%; P<0.05). The D5 HB rate was much higher than the D6 HB rate (61.6% vs. 29.4%; P<0.05). There were 21% (40/195) of cycles that only had D6 blastocysts, of which IVF cycles were lower than ICSI (19.8% vs. 28.5%; P<0.05). The clinical pregnancy rate and implantation rate in the D5 group were significantly higher than the rates in the D6 group (57.4% vs. 46.2%, 58.9% vs. 47.3%; P0.05).